Industry – collaborate with us
Partner with us to translate discoveries into impact
We actively partner with industry to accelerate the development and delivery of therapies, diagnostics, and digital tools for rare respiratory diseases.
Why collaborate with the Centre?
Access to validated models
Work with our disease-relevant organoids, airway cell lines, and phenotypic screening platforms to test and refine therapeutic candidates.
Expertise in genetic therapies
Collaborate with us to advance treatments using innovative non-viral approaches. These include antisense oligonucleotides (ASOs, which can selectively alter gene expression), genome editing tools and messenger RNA Lipid Nanoparticles (mRNA-LNPs, a sophisticated delivery system for genetic instructions).
De-risked translational pathway
Engage in plug-and-play therapeutic development using our biobank and registry.
Engaged patient network
Connect with a highly involved patient community, enabling meaningful co-design and faster recruitment.
Industrial forums & joint projects
Join our regular hybrid meetings and networking sessions to develop non-competitive collaboration opportunities and co-funded initiatives.
Let’s build the future of rare respiratory care – together
If you’re a biotech, pharma, MedTech, diagnostics or digital health company, we invite you to collaborate, invest, or co-develop with us.